Cutaneous T-cell Lymphoma Clinical Trial
Official title:
A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas
The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin. The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT02881749 -
Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
|
Phase 2 | |
Completed |
NCT00744991 -
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00099593 -
Immunization Against Tumor Cells in Sezary Syndrome
|
Phase 2 | |
Completed |
NCT02593045 -
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
|
Phase 1 | |
Recruiting |
NCT00779896 -
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT00177268 -
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
|
||
Completed |
NCT01728805 -
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
|
Phase 3 | |
Withdrawn |
NCT00969085 -
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
|
Phase 2 | |
Completed |
NCT00412997 -
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
|
Phase 1 | |
Completed |
NCT00254332 -
Effect of Denileukin Diftitox on Immune System in CTCL Patients
|
N/A | |
Recruiting |
NCT04296786 -
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study
|
Phase 2 | |
Recruiting |
NCT06285370 -
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
|
Phase 4 | |
Completed |
NCT00071084 -
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
|
Phase 2 | |
Completed |
NCT00896493 -
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
|
Phase 2 | |
Terminated |
NCT00699296 -
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
|
Phase 2 | |
Completed |
NCT02676778 -
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
|
Phase 2 | |
Terminated |
NCT02061449 -
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
|
Phase 1 | |
Completed |
NCT01134341 -
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 |